We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PET, SPECT Infusion Enhancements Streamline Infusion Scheduling

By HospiMedica International staff writers
Posted on 29 May 2012
Platforms have been developed for the controlled administration of molecular agents for single photon emission tomography (SPECT) as well as information technology (IT) enhancements to streamline positron emission tomography (PET) infusion scheduling.

Bayer Healthcare--Radiology & Interventional (Tarrytown, NY, USA) will present new device technologies at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami (FL, USA), June 9-13, 2012. More...
The new technology includes enhancements to the Intego PET infusion system, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures.

In PET, the Medrad Intego system is a worldwide market leader and the only US Food and Drug Administration (FDA)-cleared system for administration of 18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF). Bayer has continued to advance and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and considerably reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics systems for Intego, including wireless integration to hospital information systems/radiology information systems/picture archiving and communication systems (HIS/RIS/PACS), which simplify downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which subsequently will streamline workflow and improve efficiency for PET imaging clinics.

Doug Descalzi, Bayer senior director of molecular devices, said, “Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians

Moreover, the company will present developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging in a scientific exhibition.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer, AG (Leverkusen, Germany, is one of the world’s leading companies in the healthcare and medical products industry. The company combines the global activities of the animal health, consumer care, medical care, and pharmaceuticals divisions.

Related Links:

Bayer Healthcare



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Radiofrequency Generator
GX1
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.